CRF Health Selected by Top Tier Pharma Companies for Women's Oncology Trials
CRF Health, the leading global provider of eCOA solutions for the life sciences industry, announces agreements with two top tier pharmaceutical companies to support drug development initiatives in women's health. Selected for three high priority oncology studies for three new molecular entities, CRF Health's TrialMax® platform will support data capture for quality of life issues during the post-progression phase.
The three large scale studies into ovarian cancer and breast cancer will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific. For post-progression studies, the move from paper-based data collection to electronic methods is vital to providing unobtrusive and convenient care for patients too ill to visit study sites. CRF Health's TrialMax Touch® handheld patient diary will be used to support patients during these critical multi-year research initiatives, driving the collection of data that enhances these sponsors' data packages.
"We are pleased to have been selected as a partner of choice for these important drug development initiatives in women's oncology", said John Blakeley, Chief Business Officer at CRF Health. "With experience supporting more than 90 oncology studies, we are at the forefront of electronic data collection in this area. Our solution has been selected due to its unique design which allows us to collect data from patients in sensitive circumstances. We have given careful consideration to design a system with a more holistic approach to data capture in these uniquely challenging studies, ensuring ease-of-use for patients while making certain care remains at the center of clinical trials."
For further information on CRF Health, please visit www.crfhealth.com
About CRF Health
CRF Health is the leading provider of electronic Clinical Outcome Assessment (eCOA) solutions for global clinical trials. With experience in more than 650 trials, over 100 languages and across 74 countries, CRF Health’s TrialMax eCOA solutions consistently demonstrate the industry’s highest data accuracy, patient and site compliance, and patient retention.
CRF Health’s TrialMax eCOA solutions improve trial engagement by fitting into the lives of patients and seamlessly integrating into sites to maximize protocol compliance. Their eCOA solutions include PROs (Patient Reported Outcomes), ObsROs (Observer Reported Outcomes) and ClinROs (Clinician or Rater Reported Outcomes).
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
